GIBSON DUNN

Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Firm News | October 28, 2025

Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters' option to purchase additional shares for gross proceeds of $155.3 million.

Our corporate team was led by partners Ryan Murr, Branden Berns, and Melanie Neary and included associates Candice Johnson, Jasmine Vitug, and Anika Gidwani.

Related People

Ryan A. Murr

Branden C. Berns

Melanie E. Neary

Candice D. Johnson

Jasmine L. Vitug

Anika Gidwani

Related Capabilities

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**